Oncotarget

Research Papers:

Interleukin-10 rs1800896 polymorphism is associated with increased head and neck cancer risk but not associated with its clinical stages

Wei Huang _, Juan Song, Xiao-Wei Jia, Yin-Xue Chen, Jia Shi and Xun Jiang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:37217-37224. https://doi.org/10.18632/oncotarget.16660

Metrics: PDF 2322 views  |   HTML 1804 views  |   ?  


Abstract

Wei Huang1,*, Juan Song2,*, Xiao-Wei Jia3,*, Yin-Xue Chen1, Jia Shi1, Xun Jiang3

1Department of Stomatology, Zhuhai People's Hospital, Zhuhai Hospital Affiliated with Jinan University, Zhuhai 519099, China

2Department of Clinical Laboratory, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

3Department of Stomatology, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou 510800, China

*Co-first authors

Correspondence to:

Wei Huang, email: [email protected]

Keywords: interleukin-10, polymorphism, head and neck neoplasms, mouth neoplasms, oropharyngeal neoplasms

Received: February 13, 2017     Accepted: March 21, 2017     Published: March 29, 2017

ABSTRACT

Background: The association of interleukin-10 rs1800896 polymorphism with head and neck cancer risk and its clinical stages has been investigated by many published studies, but the results remain inconsistent. Therefore, we conducted this meta-analysis for further investigation.

Results: Six case-control studies involving 1,781 head and neck cancer patients and 1,978 controls were yielded. The results indicated an association between rs1800896 polymorphism and increased head and neck risk [odds ratio (95%confidence interval) for G vs. A, GA vs. AA, GG vs. AA, GA+GG vs. AA, and GG vs. AA + GA were 1.63 (1.30–2.04), 3.17 (2.11–4.76), 1.63 (1.17–2.26), 1.73 (1.25–2.39), and 2.73 (1.82–4.09), respectively]. The subgroup analyses all obtained similar results with overall populations. The results of clinical stages yielded a non-significant association. No publication bias was detected.

Materials and Methods: The PubMed and Chinese National Knowledge Infrastructure databases were searched up to December 27, 2016. Two authors independently selected studies, extracted and analyzed the data using the RevMan 5 software. Either a fixed effect or a random effect model was used to estimate pooled odds ratio and its 95% confidence intervals.

Conclusions: We concluded that interleukin-10 rs1800896 polymorphism was significantly associated with head and neck cancer risk but not with the clinical stages thereof.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16660